INO 3510

Drug Profile

INO 3510

Alternative Names: Fluprime; INO-3401/INO-3605/INO-3609; INO-3401/INO-3609/INO-3605; INO-3510; INO-3605/INO-3401/INO-3609; INO-3605/INO-3609/INO-3401; INO-3609/INO-3605/INO-3401; INO-3609/INO3401/INO-3605; Multi-subtype SynCon® vaccine targeting H1N1 and H5N1 influenza - Inovio; Seasonal flu vaccine (H5N1 + H1N1) - Inovio; SynCon H5N1 + H1N1 influenza universal vaccine - Inovio; Universal influenza (H5N1 + H1N1) SynCon vaccine - Inovio; VGX-3510

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Class Influenza A virus H1N1 vaccines; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype

Most Recent Events

  • 02 May 2016 INO 3510 is still in phase I trials for Influenza-A virus H5N1 & H1N1 subtypes (Prevention, In volunteers) in USA
  • 01 Feb 2014 Inovio Pharmaceuticals completes a phase I trial for Influenza-A virus H1N1 subtype (prevention, in healthy volunteers) in USA (NCT01405885)
  • 31 May 2011 Phase-I clinical trials in Influenza-A virus H5N1 subtype (prevention in volunteers) in USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top